|
Dr. Gary Patou is an Executive Partner at MPM Capital. Previously, he was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals, Inc., following its merger with GeneSoft Pharmaceuticals in 2004. As President of Genesoft, Dr. Patou was instrumental in applying for and obtaining FDA approval of the Company's lead product, FACTIVE® tablets. Prior to joining Genesoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President & Director, Project and Portfolio Management, managing all of the company's pharmaceutical development projects including FACTIVE, as well as FDA-approved products Avandia, Paxil and Augmentin. Dr. Patou also served as Director and Vice President of Anti-Infective Development where he managed the development of a broad line of anti-infective products, including oral, IV and topical antibiotics. He is a member of the Board of Directors of Oscient (NASDAQ:OSCI) and Xenon Pharmaceuticals, Inc. Concurrent to his post at MPM Capital, he also served as interim EVP and CMO of Cerimon Pharmaceuticals as well as Chairman of its Scientific Advisory Board where he continues to be a member. He also served as interim CMO of Peplin, Ltd. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds medical and medical Ph.D. degrees from University College London. | 